On the other hand, specimens from two of the three sufferers with principal FSGS in this series acquired diffuse and solid linear podocyte B7-1 staining , which was similar to the staining in the specimen from Individual 5 . In keeping with previous results,4 specimens from all three individuals with lupus nephritis experienced moderate-to-strong granular staining in podocytes or mesangium . Specimens from sufferers with IgA nephropathy demonstrated weak mesangial staining but no podocyte B7-1 staining . The strongest B7-1 staining was seen in specimens from patients with membranous nephropathy, both PLA2R-positive and PLA2R-unfavorable11 . Among allograft-biopsy specimens, B7-1 staining was observed in the specimen from the one patient with recurrent FSGS in this series , that was similar to the findings in the specimens from Sufferers 1 and 3 .Patients were responsible for obtaining their own medications, as would occur in true to life. Study Patients The two trials, which were conducted at 53 main care practices in britain, enrolled patients 12 to 80 years of age with a physician’s diagnosis of asthma. In the first-range controller therapy trial, eligible sufferers had asthma symptoms considered by their doctor to require initiation of asthma-controller therapy. In the add-on therapy trial, eligible individuals got received an inhaled glucocorticoid for at least 12 several weeks and had symptoms requiring a rise in therapy.